Effient and Caduet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Effient (prasugrel hydrochloride) and Caduet (amlodipine besylate; atorvastatin calcium). Common drug interactions include angina pectoris among females and myocardial infarction among males.

The phase IV clinical study analyzes what interactions people have when they take Effient and Caduet. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Effient?

Effient has active ingredients of prasugrel hydrochloride. It is often used in stent. eHealthMe is studying from 9,482 Effient users. Check the latest studies of Effient.

What is Caduet?

Caduet has active ingredients of amlodipine besylate; atorvastatin calcium. It is often used in high blood pressure. eHealthMe is studying from 5,157 Caduet users. Check the latest studies of Caduet.

On Jul, 31, 2026

13 people who take Effient and Caduet together, and have interactions are studied.

What are the common drug interactions of Effient and Caduet, by gender? *:

female:

Angina pectoris (chest pain due to ischemia of the heart muscle)
Back injury
Carpal tunnel syndrome (nerve compression at wrist results numbness weakness, pain , swelling)
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Eye disorder
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Limb injury
Multiple fractures
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)

male:

Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Abdominal pain upper
Silent myocardial infarction (a heart attack without having any symptoms)
Bladder neoplasm (bladder tumour)
Cardiac failure
Cystitis (inflammation of the wall of the bladder)
Death
Ear pain
Flushing (the warm, red condition of human skin)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)

What are the common drug interactions of Effient and Caduet, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Ear pain
Flushing (the warm, red condition of human skin)
Pruritus (severe itching of the skin)

60+:

Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Arterial occlusive disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked)
Drug ineffective
Bladder neoplasm (bladder tumour)
Cardiac failure
Cystitis (inflammation of the wall of the bladder)
Death
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Rectal haemorrhage (bleeding from anus)
Skin reaction

What are the existing conditions these people have? *

High Blood Cholesterol: 6 people, 46.15%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 38.46%
Diabetes: 2 people, 15.38%
Cardiac Disorder: 2 people, 15.38%
Blood Pressure Abnormal: 2 people, 15.38%
Hyperkalemia (damage to or disease of the kidney): 1 person, 7.69%
Heart Attack: 1 person, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.69%
Chest Pain: 1 person, 7.69%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Effient and Caduet?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously